Science Advances

Supplementary Materials

The PDF file includes:

  • Fig. S1. PRSS1 expression is significantly altered in colon cancer cells.
  • Fig. S2. Altering PRSS1 expression affected cetuximab inhibition of PI3K/AKT and MEK/ERK through cleavage of cetuximab, thus decreasing its effectiveness.
  • Fig. S3. PRSS1 cleaves cetuximab in a novel manner.
  • Fig. S4. Modified mAbs avoid PRSS1-mediated cleavage.
  • Fig. S5. SPINK1 effectively inhibits PRSS1 cleavage of mAbs.
  • Fig. S6. Cetuximab or bevacizumab combined with SPINK1 results in a synergistic reduction in colon cancer cell growth in vivo.
  • Fig. S7. Serum PRSS levels in patients with mCRC treated with chemotherapy before and after treatment with cetuximab.
  • Fig. S8. PRSS1 led to poor mAb effectiveness in cancer.
  • Table S1. Gene expression (PRSS1, PRSS2, and PRSS3) in a panel of cell lines (n = 49), including cell lines (n = 19) resistant to cetuximab and cell lines (n = 30) sensitive to cetuximab.
  • Table S2. Univariate and multivariate analyses of factors affecting PFS in patients who received cetuximab monotherapy.
  • Legends for data file S1A to C

Download PDF

Other Supplementary Material for this manuscript includes the following:

  • Data file S1A (Microsoft Excel format). The clinical information and test results of patients with mCRC treated with cetuximab.
  • Data file S1B (Microsoft Excel format). The clinical information and test results of patients with mCRC treated with chemotherapy or other modalities.
  • Data file S1C (Microsoft Excel format). The PRSS1 test results of the healthy controls.

Files in this Data Supplement: